Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Innventure Set to Join the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
-
Apolosign Unveils Three Family-Friendly Holiday Gifts as Americans Seek Practical, Heartwarming Tech This Season
-
zSpace Announces Strategic Restructuring to Strengthen Financial Foundation
-
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
-
VEON’s Banglalink Receives Regulatory Approval to Launch Digital Payment Services to Advance Financial Inclusion in Bangladesh
-
Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229
-
Kalbe Farma and LIFE AI Unveil StrokeGENME to Personalize Stroke Prevention at National Scale
-
Sprott Physical Silver Trust Updates Its “At-the-Market” Equity Program
-
RentStac Announces Presale Milestone Surpassing $1.5 Million Amid Growing Interest in Real Estate Tokenization
-
byNordic Acquisition Corporation Announces Extension of Deadline to Complete Business Combination
-
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
-
B2BROKER Releases B2CORE Updates, Strengthening Its All-in-One CRM Ecosystem
-
Form 8.3 - Idox Plc
-
Form 8.3 - Empiric Student Property Plc
-
Form 8.3 - Bluefield Solar Income Fund Ltd
-
Plus Therapeutics Expands CNSide Assay Platform to State of California
-
Caliber Commences LINK Staking to Support Chainlink Node Program
-
Beneficient Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
-
Domestic Metals Announces Gord Neal as CEO
-
Patria Investments Announces Acquisition of RBR Gestão, adding US$ 1.5 bn in Listed Real Estate Investment Trusts (“REITs”) in Brazil
-
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
-
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
-
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
-
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines
-
Brink’s Announces New $750M Share Repurchase Authorization
-
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
-
BitMEX Debuts New Mobile Trading Experience With Intuitive Design and Controls
-
Dimensional Fund Advisors Ltd. : Form 8.3 - AMERICAN AXLE & MFG HOLDINGS - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - BAKKAVOR GROUP PLC - Ordinary Shares
-
Danske Bank A/S, transactions by persons discharging managerial responsibilities
-
Dimensional Fund Advisors Ltd. : Form 8.3 - GREENCORE GROUP PLC - Ordinary Shares
-
PEGASUS Takes the Next Step: First Aircraft Lands in Germany
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PERSONAL FINAN - Ordinary Shares
-
Digital Currency X Technology Inc. Completes $1 Billion EdgeAI Token Acquisition, Treasury Holdings Exceeding $1.4 Billion
-
Dimensional Fund Advisors Ltd. : Form 8.3 - JUST GROUP PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
-
Superbet Group becomes Super Technologies, shaping the future of digital entertainment ecosystems
-
New Crypto Mutuum Finance (MUTM) Nears 100% Phase 6 Allocation as Funding Approaches $20M
-
Dimensional Fund Advisors Ltd. : Form 8.3 - TT ELECTRONICS PLC - Ordinary Shares
-
Company announcement regarding the preliminary result of the mandatory tender offer to the shareholders of Copenhagen Airports A/S
-
Keiretsu Forum and MDB Capital Close 2025 With High-Impact Investor Summits, and Announces Expanded Summit Series for 2026
-
Apollo Silver Announces 2026 Exploration and Development Program for its U.S. based Calico Project
-
Goodfood Announces Management Change
-
Nevada Lithium Announces Winter Work Program Focused on Further Enhancing Value of the Bonnie Claire Lithium & Boron Project
-
Asante Provides Financial and Operating Results for the Quarter Ended October 31, 2025
-
Bastion Strengthens US Public Relations Offering with New Hire Jody Sowa as Managing Director
-
McFarlane Targets Resource Expansion at Juby Gold Project
-
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
-
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
-
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer
